Email this article Mesonephric (clear cell) endometrial cancer
- Authors: Ulrikh E.A.1, Khalimbekova D.I.2, Urmancheyeva A.F.2, Matsko D.Y.3, Merabishvili V.M.4
-
Affiliations:
- Saint-Petersburg State Pediatric Medical Academy
- North-Western State Medical I. I. Mechnikov-University
- N. N. Petrov Research Institute of Oncology
- Medical Information Analytic Center
- Issue: Vol 61, No 5 (2012)
- Pages: 85-91
- Section: Articles
- URL: https://journals.rcsi.science/jowd/article/view/1311
- DOI: https://doi.org/10.17816/JOWD61585-91
- ID: 1311
Cite item
Full Text
Abstract
Clear Cell Endometrial Cancer is a rare nonendometrioid endometrial carcinoma detected in 1–6 %. The aim of the study was to determine clinical and morphologic features of Clear Cell Endometrial Cancer. Materials: All the cases with Clear Cell Endometrial Cancer treated in the N. N. Petrov Research Institute of Oncology (Saint-Petersburg) were identified from surgical pathology files from 1985 to 2010 years. Saint-Petersburg Population Cancer Registry data (2000–2005 years period) and N. N. Petrov Research Institute of Oncology Hospital Cancer Registry data (1985–2010 years period) were analyzed. The population based study included 3 224 cases of endometrial cancer patients, the hospital study — 3 345 patients. Results: A review of 3 345 cases of endometrial cancer revealed 73 cases (2.2 %) of Clear Cell Endometrial Cancer. Clear Cell Endometrial Cancer registered in elder women with late menopause and atrophic endometrium. The tumor is a highly malignant variant of endometrial carcinoma with deep myometrial invasion (42.5 %), high rate of metastasis (39.1 %) even in cases with superficial invasion (23.0 %) versus endometrioid endometrial cancer: 6.0 %, 14.2 % and 9.0 % respectively. Clear Cell Endometrial Cancer has a poor prognosis with 3-year observed survival 62.7 %, 5-year observed survival — 52.2 % (Saint-Petersburg Population Cancer Registry), 70.9 % (3-year survival) and 61.8 % (5-year survival) according to the N. N. Petrov Research Institute of Oncology Hospital Cancer Registry data. Whereas prognosis in patients with endometrioid endometrial carcinoma is much more favorable: 3-year observed survival 79.4 %, 5-year observed survival — 75.5 %
Full Text
##article.viewOnOriginalSite##About the authors
Elena Aleksandrovna Ulrikh
Saint-Petersburg State Pediatric Medical Academy
Email: spb@gpma.ru
doctor of medical sciences, professor
Dzhamilat Ilyasovna Khalimbekova
North-Western State Medical I. I. Mechnikov-University
Email: dzhamilya05@mail.ru
postgraduate of a department of oncology
Adiliya Fettekhovna Urmancheyeva
North-Western State Medical I. I. Mechnikov-University
Email: oncli@rion.spb.ru
doctor of medical sciences, professor of a department of oncology
Dmitriy Yevgenyevich Matsko
N. N. Petrov Research Institute of Oncology
Email: oncli@rion.spb.ru
doctor of medical sciences, professor. Head of patologoanatomic laboratory
Vakhtang Mikhaylovich Merabishvili
Medical Information Analytic Center
Email: MerabishviliV@miac.zdrav.spb.ru
doctor of medical sciences, professor
References
- Ульрих Е. А., Нейштадт Э. Л. Редкие формы рака тела матки // Практическая онкология. — 2004. — Т. 5, № 1. — С. 68–76.
- Урманчеева А. Ф. Лекарственная терапия рака эндометрия // Практическая онкология: избранные лекции. — СПб., 2008. — С. 400.
- Чиссов В. И., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность) . — М., 2012. — 260 с.
- Bokhman J. V. Two pathogenetic types of endometrial carcinoma // Gynecol. Oncol. — 1983. — Vol. 15. — P. 10–17.
- Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern / Abeler V. M., Vergote I. B. [et al.] // Cancer. — 1996. — Vol. 78. — Р. 1740–1747.
- Global cancer statistics, 2002 / Parkin D. M. [et al.] // C A. Cancer. J. Clin. — 2005. — Vol. 55. — P. 74–108.
- Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? / Kwon J. S. [et al.] // Int. J. of Gynecol. Cancer. — 2008. — Vol. 18. — P. 820–824.
- Kurman R. J., Norris S. J. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma // Cancer. — 1986. — Vol. 49. — P. 2547–2549.
- P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis / Sherman M. E. [et al.] // Hum. Pathol. — 1995. — Vol. 26. — P. 1268–1274.
- Pattern of recurrence in endometrial cancer: a retrospective CTF studi / Sartori E. [et al.] // Endometrial Cancer. — 1999. — Vol. 12. — P. 80.
- Saia di P. J., Creasman W.T. Clinical Gynecologic Oncology. — St. Louis, 1992.
- Schiller W. Mesonephroma ovarii // Am. J. Cancer. — 1939. — P. 351.
- Scully R. E., Barlow J. F. «Mesonefroma» of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma // Cancer. — 1967. — Vol. 20. — P. 1405.
- Silverberg S., Kurman R. Tumours of the uterine corpus and gestational trophoblastic disease // Atlas of tumor pathology / Armed forces institute of pathology. — Third Series. — Washington D. C. ,1992. — P. 240–288.
- Stewart K., Martinez A., Weiner S. Ten-year outcome including pattern of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma // Int. J. Radiat. Oncol. Biol. Phys. — 2002. — Vol. 54. — P. 527.
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage — 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma / Creutzberg C. L. [et al.] // Lancet. — 2000. — Vol. 355. — P. 1404–1411.
- Tavassoli F., Devilee P. Tumours of the breast and female genital organs / World Health Organization. — Lion, 2003.
- Trope C., Kristensen G. B., Abeler V. M. Clear cell and papillary serous cancer: treatment options // Baillieres Best. Pract. Res. Clin. Obstet. Gynecol. — 2001. — Vol. 15, N 3. — P. 433–446.
Supplementary files
